Physician profile
Catherine A Soller
NPI 1528290558
$33,146.89
in general payments reported to CMS, 2019-2025
28 companies · $2,111 in 2025
The $2,111 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $6,859 · 2022: $16K · 2023: $6,330 · 2024: $2,139 · 2025: $2,111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,900 · Food and Beverage: $4,660 · Education: $20.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,900.00 |
| Food and Beverage | $4,659.56 |
| Education | $20.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $17,695.62 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Tandem Diabetes Care, INC. | $8,231.97 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,352.42 | 2021-2025 | Jardiance, Synjardy |
| Lilly USA, LLC | $1,137.34 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Dexcom, INC. | $708.59 | 2021-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $700.06 | 2022-2025 | |
| Amgen INC. | $658.06 | 2021-2025 | Evenity, Tepezza, Prolia |
| Astrazeneca Pharmaceuticals LP | $399.94 | 2021-2025 | Farxiga |
| Sanofi-Aventis U.S. LLC | $318.63 | 2021-2023 | |
| Insulet Corporation | $315.50 | 2021-2025 | Omnipod |
| Abbott Laboratories | $291.98 | 2021-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $254.07 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $182.32 | 2021-2025 | Recorlev, Gvoke Hypopen |
| Recordati_rare_diseases_inc. | $160.28 | 2024-2025 | Isturisa, Signifor Lar |
| Acella Pharmaceuticals, LLC | $139.93 | 2024-2025 | NP Thyroid 60 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $93.79 | 2022-2024 | Korlym |
| Horizon Therapeutics Plc | $80.10 | 2023 | Tepezza |
| Amarin Pharma, INC. | $77.31 | 2021 | |
| Medtronic, INC. | $48.74 | 2022-2024 | Minimed 780g, Intellis Adaptivestim |
| Radius Health, INC. | $44.72 | 2022 | |
| Avion Pharmaceuticals | $43.70 | 2022-2024 | NP Thyroid 60 |
| Abbvie INC. | $42.97 | 2021-2022 | |
| Ibsa Pharma INC. | $38.34 | 2021 | |
| Ascendis Pharma Endocrinology INC | $37.16 | 2025 | Yorvipath |
| Alexion Pharmaceuticals, INC. | $31.02 | 2024 | Strensiq |
| Janssen Pharmaceuticals, INC | $30.60 | 2021-2022 | |
| Averitas Pharma INC. | $17.45 | 2024 | Qutenza |
| Ascensia Diabetes Care US INC. | $14.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Soller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.